Stevanato Group S.p.A. (STVN) Stock
Key stats
- Market cap
- $3.80B
- Price / Earnings ratio
- 26.1x
- EPS (TTM)
- $0.57
- Volume
- Loading
- 52-week high
- $25.45
- 52-week low
- $12.05
Source: third-party data provider, as of November 13, 2026
Compare with STVN
Recent news

Stevanato Group (STVN) Surpasses Q3 Earnings and Revenue Estimates
Stevanato Group (STVN) Surpasses Q3 Earnings and Revenue Estimates
STVN

Stevanato Group Delivers 8% Revenue Growth for the Third Quarter of Fiscal 2026
Stevanato Group Delivers 8% Revenue Growth for the Third Quarter of Fiscal 2026
STVN

Stevanato Group and Aptar Pharma Collaborate to Help Accelerate Pre-Filled Syringe System Selection
Stevanato Group and Aptar Pharma Collaborate to Help Accelerate Pre-Filled Syringe System Selection
STVN

Stevanato Group to Report Third Quarter 2026 Financial Results on November 3, 2026
Stevanato Group to Report Third Quarter 2026 Financial Results on November 3, 2026
STVN
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 27.10
- MACD 12/26/9
- -1.74
- EMA 9 of MACD
- -1.26
- MACD histogram
- -0.48
- SMA 50
- $19.37
- Price below SMA 50
- EMA 50
- $18.47
- Price below EMA 50
- SMA 200
- $17.93
- Price below SMA 200
- EMA 200
- $18.66
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Stevanato Group (STVN) Surpasses Q3 Earnings and Revenue Estimates
Stevanato Group (STVN) Surpasses Q3 Earnings and Revenue Estimates
STVN

Stevanato Group Delivers 8% Revenue Growth for the Third Quarter of Fiscal 2026
Stevanato Group Delivers 8% Revenue Growth for the Third Quarter of Fiscal 2026
STVN

Stevanato Group and Aptar Pharma Collaborate to Help Accelerate Pre-Filled Syringe System Selection
Stevanato Group and Aptar Pharma Collaborate to Help Accelerate Pre-Filled Syringe System Selection
STVN

Stevanato Group to Report Third Quarter 2026 Financial Results on November 3, 2026
Stevanato Group to Report Third Quarter 2026 Financial Results on November 3, 2026
STVN

Stevanato Group to Participate in Two Upcoming Investor Conferences
Stevanato Group to Participate in Two Upcoming Investor Conferences
STVN

Stevanato Group Q2 Earnings Call Highlights
Stevanato Group Q2 Earnings Call Highlights
STVN

Is Stevanato (STVN) a Solid Growth Stock? 3 Reasons to Think "Yes"
Is Stevanato (STVN) a Solid Growth Stock? 3 Reasons to Think "Yes"
STVN

Stevanato Group (STVN) Q2 Earnings Top Estimates
Stevanato Group (STVN) Q2 Earnings Top Estimates
STVN

Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026
Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026
STVN

Liraglutide Combination Products Incorporating Stevanato Group's Alina® Pen Injector Received Marketing Authorizations in Multiple European Countries
Liraglutide Combination Products Incorporating Stevanato Group's Alina® Pen Injector Received Marketing Authorizations in Multiple European Countries
STVN
News tone: automated (AI) classification of the article's content, not a price prediction.
About Stevanato Group S.p.A.
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Franco Stevanato | CEO & Executive Chairman | 1973 |
| Mr. Marco Dal Lago | Chief Financial Officer | 1973 |
| Ms. Lisa Miles | Chief Communications & Investor Relations Officer | — |
| Ms. Carla Costa | Chief Human Resources Officer | — |
| Mr. Mauro Stocchi | Chief Business Officer | 1967 |
| Mr. Michele Monico | President of DDS & IVD Business Unit | — |
| Mr. Raffaele Pace | President of Engineering Business Unit | — |
Fundamentals
Valuation
Profitability
Trading
Dividend
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 27.10
- MACD 12/26/9
- -1.74
- EMA 9 of MACD
- -1.26
- MACD histogram
- -0.48
- SMA 50
- $19.37
- Price below SMA 50
- EMA 50
- $18.47
- Price below EMA 50
- SMA 200
- $17.93
- Price below SMA 200
- EMA 200
- $18.66
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $16.00
- Average
- $19.67
- High
- $23.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -2.6 | -1.3 | -8.9 | +23.6 | +5.4 | -4.2 | +8.2 | +4.1 | +1.3 | -3.0 | -29.5 |
Corporate actions
Upcoming
No upcoming corporate actions for STVN



